{"id":2391,"date":"2019-10-05T22:59:25","date_gmt":"2019-10-05T20:59:25","guid":{"rendered":"https:\/\/idibell.cat\/?page_id=2391"},"modified":"2024-12-17T11:14:43","modified_gmt":"2024-12-17T10:14:43","slug":"cancer-immunotherapy","status":"publish","type":"page","link":"https:\/\/idibell.cat\/en\/research\/cancer-area\/molecular-mechanisms-and-experimental-therapy-in-oncology-program-oncobell\/cancer-immunotherapy\/","title":{"rendered":"Cancer Immunotherapy"},"content":{"rendered":"\n<h1>\n\t\tCancer immunotherapy\n\t<\/h1>\n<h3>\n\t\tSummary\n\t<\/h3>\n\t<p>The Cancer Virotherapy and Immunotherapy Group explores new anticancer treatments based on oncolytic adenoviruses and other immunotherapies. The group aims to design and evaluate oncolytic adenoviruses as antitumour agents for various solid tumours. The main lines of research are tumour targets, intratumoural diffusion through stromal barriers and oncolytic immunotherapy. The group also participates in other immunotherapy projects based on mutanome-derived cancer neoepitopes and cellular immunotherapy with modified NK cells.\u00a0\u00a0<\/p>\n<h2>243<\/h2>\n<h2>Publications<\/h2>\n\t\t\t\t<img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/idibell.cat\/en\/wp-content\/uploads\/sites\/2\/2020\/04\/103-viroterapiadelcancer-ralemany-def.jpeg\" alt=\"103-viroterapiadelcancer-ralemany-def\" itemprop=\"image\" height=\"300\" width=\"600\" title=\"103-viroterapiadelcancer-ralemany-def\" onerror=\"this.style.display='none'\"  \/>\n\t\t\t\t\t<a href=\"#\" id=\"fl-accordion--label-0\" tabindex=\"0\" aria-controls=\"fl-accordion--panel-0\">Strategic lines<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<a href=\"#\" id=\"fl-accordion--icon-0\" tabindex=\"-1\"><i title=\"Expand\">Expand<\/i><\/a>\n\t\t\t\t\t<p>Research for oncolytic adenovirus tumour targets (Ramon Alemany)<\/p>\n<p>Intratumoural diffusion of oncolytic adenoviruses through stromal barriers (Ramon Alemany)<\/p>\n<p>Oncolytic immunotherapy (Ramon Alemany \/ Rafa Moreno)<\/p>\n<p>Immunotherapy based on cancer neoepitopes (Ramon Alemany \/ Rafa Moreno \/ Josep Maria Piulats \/ V\u00edctor Moreno)<\/p>\n<p>Mesenchymal stem cells as carriers of oncolytic adenoviruses (Rafa Moreno)<\/p>\n<p>Laboratory analysis associated with clinical trials with oncolytic adenoviruses (Rafa Moreno and Marcel Costa)<\/p>\n\t\t\t\t\t<a href=\"#\" id=\"fl-accordion--label-1\" tabindex=\"0\" aria-controls=\"fl-accordion--panel-1\">Selected Publications<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<a href=\"#\" id=\"fl-accordion--icon-1\" tabindex=\"-1\"><i title=\"Expand\">Expand<\/i><\/a>\n\t\t\t\t\t<ul>\n<li>Fizazi,K;Piulats,JM;Reaume,MN;Ostler,P;McDermott,R;Gingerich,JR;Pintus,E et al, <strong>Rucaparib or Physician&#8217;s Choice in Metastatic Prostate Cancer<\/strong>., N. Engl. J. Med., 2023;388(8):719-732, doi:10.1056\/NEJMoa2214676<\/li>\n<li>Hassel,JC;Piperno Neumann,S;Rutkowski,P;Baurain,JF;Schlaak,M;Butler,MO;Sullivan,RJ et al, <strong>Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma<\/strong>, N. Engl. J. Med., 2023;389(24):2256-2266, doi:10.1056\/NEJMoa2304753<\/li>\n<li>Piulats,JM;Watkins,C;Costa Garc\u00eda,M;Del Carpio,L;Piperno Neumann,S;Rutkowski,P;Hassel,JC et al, <strong>Overall survival from tebentafusp versus nivolumab plus ipilimumab in first-line metastatic uveal melanoma: a propensity score-weighted analysis<\/strong>., Ann. Oncol., 2023;doi:10.1016\/j.annonc.2023.11.013<\/li>\n<li>Piulats,JM;Watkins,C;Costa Garc\u00eda,M;Del Carpio,L;Piperno Neumann,S;Rutkowski,P;Hassel,JC et al, <strong>Overall survival from tebentafusp versus nivolumab plus ipilimumab in first-line metastatic uveal melanoma: a propensity score-weighted analysis<\/strong>., Ann. Oncol., 2023;doi:10.1016\/j.annonc.2023.11.013<\/li>\n<li>Garofalo,M;Wieczorek,M;Anders,I;Staniszewska,M;Lazniewski,M;Prygiel,M;Zasada,AA et al, <strong>Novel combinatorial therapy of oncolytic adenovirus AdV5\/3-D24-ICOSL-CD40L with anti PD-1 exhibits enhanced anti-cancer efficacy through promotion of intratumoral T-cell infiltration and modulation of tumour microenvironment in mesothelioma mouse model<\/strong>, Front. Oncol., 2023;131259314-1259314, doi:10.3389\/fonc.2023.1259314<\/li>\n<\/ul>\n\t\t\t\t\t<a href=\"#\" id=\"fl-accordion--label-2\" tabindex=\"0\" aria-controls=\"fl-accordion--panel-2\">Selected Projects<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<a href=\"#\" id=\"fl-accordion--icon-2\" tabindex=\"-1\"><i title=\"Expand\">Expand<\/i><\/a>\n\t\t\t\t\t<p>20FIS039. <strong>Phase II stUdy of ALoCelyvir in patientS with mEtastatic Uveal Melanoma (PULSE-UM)<\/strong>. Instituto de Salud Carlos III (ISCIII). Budget: 694.346,29\u20ac. 2020-2025. PI: Piulats Rodr\u00edguez, Josep Mar\u00eda.<\/p>\n<p>21FIS038. <strong>Venciendo la resistencia a la inmunoterapia en tumores no antig\u00e9ncios ni inmunog\u00e9nicos usando el c\u00e1ncer de pr\u00f3stata como modelo. El estudio HEAT-CRPC<\/strong>. Instituto de Salud Carlos III (ISCIII). Budget: 133.100\u20ac. 2021-2025. PI: Piulats Rodr\u00edguez, Josep Mar\u00eda.<\/p>\n<p>FIS21131. <strong>RICORS TERAV<\/strong>. Instituto de Salud Carlos III (ISCIII). Budget: 169.412,1\u20ac. 2022-2024. PI: Alemany Bonastre, Ram\u00f3n.<\/p>\n<p>FIS23018. <strong>C\u00e9lulas troncales mesenquimales como veh\u00edculo celular de un adenovirus oncolitico codificante de un activador biespecifico de c\u00e9lula T (BiTE) frente a EGFR para el tratamiento del glioblastoma<\/strong>. Instituto de Salud Carlos III (ISCIII). Budget: 95.625\u20ac. 2024-2026. PI: Moreno Oli\u00e9, Rafael.<\/p>\n<p>MCI21009. <strong>Inducci\u00f3n de muerte celular inmunog\u00e9nica en tumores mediante el uso de adenovirus oncol\u00edticos armados<\/strong>. Ministerio de Ciencia e Innovaci\u00f3n. Budget: 266.200\u20ac. 2021-2024. PI: Alemany Bonastre, Ram\u00f3n.<\/p>\n<p>2022-160-1. <strong>ESTUDIO FASE II, ABIERTO DE LA EFICACIA PRELIMINAR DE SITRAVATINIB EN COMBINACI\u00d3N CON TISLELIZUMAB EN PACIENTES CON MELANOMA METAST\u00c1SICO UVEAL CON HEP\u00c1TICAS MET\u00c1STASIS<\/strong>. Grupo Espa\u00f1ol Multidisciplinar de Melanoma (GEM). Budget: 5.000\u20ac. 2022- . PI: Piulats Rodr\u00edguez, Josep Mar\u00eda.<\/p>\n<p>18ACL149. <strong>A PHASE I\/II, OPEN-LABEL, MULTI-CENTER STUDY OF THE SAFETY AND EFFICACY OF IMCGP100 USING THE INTRA-PATIENT ESCALATION DOSING REGIMEN IN PATIENTS WITH ADVANCED UVEALMELANOMA<\/strong>. Immunocore Ireland Limited. Budget: 154.384\u20ac. 2018- . PI: Piulats Rodr\u00edguez, Josep Mar\u00eda.<\/p>\n<p>17ACL119. <strong>TRITON 3: UN ESTUDIO MULTIC\u00c9NTRICO, ALEATORIZADO, ABIERTO DE FASE 3 DE RUCAPARIB VERSUS ELECCI\u00d3N DEL M\u00c9DICO PARA PACIENTES CON C\u00c1NCER DE PR\u00d3STATA METAST\u00c1SICO RESISTENTE A LA CASTRACI\u00d3N ASOCIADO CON DEFICIENCIA DE RECOMBINACI\u00d3N HOM\u00d3LOGA<\/strong>. CLOVIS ONCOLOGY, INC. . Budget: 77.183,86\u20ac. 2017-2026. PI: Piulats Rodr\u00edguez, Josep Mar\u00eda.<\/p>\n<p>PNJ22025. <strong>Servei d&#8217;Estudis de Pot\u00e8ncia in vitro e in vivo per a c\u00e8l\u00b7lules NK derivades d&#8217;iPSC en el marc d&#8217;un projecte de recerca pel Banc de Sang i Teixits. Banc de Sang i Teixits<\/strong>. Budget: 68.600\u20ac. 2022- . PI: Moreno Oli\u00e9, Rafael.<\/p>\n<p>19PNJ011. <strong>ESTUDIO DE FASE I PARA EVALUAR LA SEGURIDAD, LA TOLERABILIDAD Y LA EFICACIA DE VCN-01 EN COMBINACI\u00d3N CON DURVALUMAB (MEDI4736) EN PACIENTES CON CARCINOMA DE C\u00c9LULAS ESCAMOSAS DE CABEZA Y CUELLO RECURRENTE \/ METAST\u00c1SICO<\/strong> . VCN BIOSCIENCES SL. 2019-2023. PI: Alemany Bonastre, Ram\u00f3n.<\/p>\n\t\t\t\t\t<a href=\"#\" id=\"fl-accordion--label-3\" tabindex=\"0\" aria-controls=\"fl-accordion--panel-3\">Technology transfer<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<a href=\"#\" id=\"fl-accordion--icon-3\" tabindex=\"-1\"><i title=\"Expand\">Expand<\/i><\/a>\n\t\t\t\t\tPAT005-ADENOVIRUS ONCOL\u00cdTICOS PARA EL TRATAMIENTO DEL C\u00c1NCER<br \/>\nIP: Ramon Alemany<br \/>\nES200901201\nPAT040-ADENOVIRUS COMPRISING AN ALBUMIN-BINDING MOIETY<br \/>\nIP: Ramon Alemany<br \/>\nEP14382162\nLicense: Adenovirus comprising an albumin-binding molety<br \/>\nPI: Dr. Ramon Alemany<br \/>\nLicense: Adenovirus onol\u00edticos para el tratamiento del c\u00e1ncer<br \/>\nPI: Dr. Manel Cascall\u00f3\n\t\t\t\t\t<a href=\"#\" id=\"fl-accordion--label-4\" tabindex=\"0\" aria-controls=\"fl-accordion--panel-4\">More Information<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<a href=\"#\" id=\"fl-accordion--icon-4\" tabindex=\"-1\"><i title=\"Expand\">Expand<\/i><\/a>\n\t\t\t\t\t<p>The viruses developed by the group are currently being tested in clinical trials conducted by biotechnology companies. These include VCN Biosciences, which is a spin-off of the group. The group also analyses viral and immunological parameters in patient samples.<\/p>\n\t\t\t\t<img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/idibell.cat\/en\/wp-content\/uploads\/sites\/2\/2019\/10\/alemany-bonastre-ramon-150x150.jpg\" alt=\"Alemany Bonastre, Ramon\" itemprop=\"image\" height=\"150\" width=\"150\" title=\"alemany-bonastre-ramon\" onerror=\"this.style.display='none'\"  \/>\n<h4>\n\t\tAlemany Bonastre, Ramon\n\t<\/h4>\n<h4>\n\t\t<a href=\"mailto:ralemany@idibell.cat\" title=\"ralemany@idibell.cat\" target=\"_blank\" rel=\"noopener\">\n\t\tralemany@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t<img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/idibell.cat\/en\/wp-content\/uploads\/sites\/2\/2023\/10\/Josep-Maria-Piulats-Rodriguez-150x150.jpg\" alt=\"Josep-Maria-Piulats-Rodriguez\" itemprop=\"image\" height=\"150\" width=\"150\" title=\"Josep-Maria-Piulats-Rodriguez\" onerror=\"this.style.display='none'\"  \/>\n<h4>\n\t\tPiulats, Rodriguez, Josep Maria\n\t<\/h4>\n<h4>\n\t\t<a href=\"mailto:jpiulats@idibell.cat\" title=\"jpiulats@idibell.cat\" target=\"_blank\" rel=\"noopener\">\n\t\tjpiulats@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n<h2>\n\t\tPrincipal investigators\n\t<\/h2>\n\t\t\t\t<img decoding=\"async\" src=\"https:\/\/idibell.cat\/wp-content\/uploads\/2019\/10\/alemany-bonastre-ramon-150x150.jpg\" alt=\"Alemany Bonastre, Ramon\" itemprop=\"image\" title=\"alemany-bonastre-ramon\" onerror=\"this.style.display='none'\"  \/>\n<h4>\n\t\tAlemany Bonastre, Ramon\n\t<\/h4>\n<h4>\n\t\t<a href=\"mailto:ralemany@idibell.cat\" title=\"ralemany@idibell.cat\" target=\"_blank\" rel=\"noopener\">\n\t\tralemany@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t<img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/idibell.cat\/en\/wp-content\/uploads\/sites\/2\/2023\/10\/Josep-Maria-Piulats-Rodriguez-150x150.jpg\" alt=\"Josep-Maria-Piulats-Rodriguez\" itemprop=\"image\" height=\"150\" width=\"150\" title=\"Josep-Maria-Piulats-Rodriguez\" onerror=\"this.style.display='none'\"  \/>\n<h4>\n\t\tPiulats, Rodriguez, Josep Maria\n\t<\/h4>\n<h4>\n\t\t<a href=\"mailto:jpiulats@idibell.cat\" title=\"jpiulats@idibell.cat\" target=\"_blank\" rel=\"noopener\">\n\t\tjpiulats@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t<img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/idibell.cat\/en\/wp-content\/uploads\/sites\/2\/2023\/04\/Rafael-Moreno-Olie-150x150.png\" alt=\"Rafael-Moreno-Olie\" itemprop=\"image\" height=\"150\" width=\"150\" title=\"Rafael-Moreno-Olie\" onerror=\"this.style.display='none'\"  \/>\n<h4>\n\t\tMoreno Oli\u00e9, Rafael\n\t<\/h4>\n<h4>\n\t\t<a href=\"mailto:rmoreno@idibell.cat\" title=\"rmoreno@idibell.cat\" target=\"_blank\" rel=\"noopener\">\n\t\trmoreno@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n<h4>\n\t\tRELATED LINKS\n\t<\/h4>\n<h4>\n\t\t<a href=\"http:\/\/ico.gencat.cat\/ca\/recerca\/Programa-ProCURE\/index.html\" title=\"ProCURE\" target=\"_blank\" rel=\"noopener\">\n\t\tProCURE\n\t\t<\/a>\n\t<\/h4>\n<h4>\n\t\t<a href=\"https:\/\/sites.google.com\/site\/adenonet\/home\" title=\"Spanish Adenovirus Network\" target=\"_blank\" rel=\"noopener\">\n\t\tSpanish Adenovirus Network\n\t\t<\/a>\n\t<\/h4>\n<h2>\n\t\tTeam\n\t<\/h2>\n\t\t\t\t\t\t\t\t<a href=\"#\" id=\"fl-tabs--label-0\" data-index=\"0\" aria-selected=\"true\" aria-controls=\"fl-tabs--panel-0\" aria-expanded=\"true\" role=\"tab\" tabindex=\"0\">\t\t\t\tGroup leaders\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t<a href=\"#\" id=\"fl-tabs--label-1\" data-index=\"1\" aria-selected=\"false\" aria-controls=\"fl-tabs--panel-1\" aria-expanded=\"false\" role=\"tab\" tabindex=\"0\">\t\t\t\tPrincipal investigators\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t<a href=\"#\" id=\"fl-tabs--label-2\" data-index=\"2\" aria-selected=\"false\" aria-controls=\"fl-tabs--panel-2\" aria-expanded=\"false\" role=\"tab\" tabindex=\"0\">\t\t\t\tClinical researchers\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t<a href=\"#\" id=\"fl-tabs--label-3\" data-index=\"3\" aria-selected=\"false\" aria-controls=\"fl-tabs--panel-3\" aria-expanded=\"false\" role=\"tab\" tabindex=\"0\">\t\t\t\tPostdoctoral researchers\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t<a href=\"#\" id=\"fl-tabs--label-4\" data-index=\"4\" aria-selected=\"false\" aria-controls=\"fl-tabs--panel-4\" aria-expanded=\"false\" role=\"tab\" tabindex=\"0\">\t\t\t\tPredoctoral researchers\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t<a href=\"#\" id=\"fl-tabs--label-5\" data-index=\"5\" aria-selected=\"false\" aria-controls=\"fl-tabs--panel-5\" aria-expanded=\"false\" role=\"tab\" tabindex=\"0\">\t\t\t\tScientific support\t\t\t\t<\/a>\n\t\t\t\t\t\tGroup leaders\n\t\t\t\t\t\t\t\t\t\t\t<ul>\n<li>Alemany Bonastre, Ram\u00f3n<\/li>\n<li>Piulats, Rodriguez, Josep Maria<\/li>\n<\/ul>\n\t\t\t\t\t\tPrincipal investigators\n\t\t\t\t\t\t\t\t\t\t\t<ul>\n<li>Moreno Oli\u00e9, Rafael<\/li>\n<\/ul>\n\t\t\t\t\t\tClinical researchers\n\t\t\t\t\t\t\t\t\t\t\t<ul>\n<li>Buisan Rueda, Oscar<\/li>\n<\/ul>\n\t\t\t\t\t\tPostdoctoral researchers\n\t\t\t\t\t\t\t\t\t\t\t<ul>\n<li>Costa Garcia, Marcel<\/li>\n<li>Espinosa Carrasco, Gabriel<\/li>\n<li>Franco Luzon, Lidia<\/li>\n<\/ul>\n\t\t\t\t\t\tPredoctoral researchers\n\t\t\t\t\t\t\t\t\t\t\t<ul>\n<li>Moya Borrego, Laura<\/li>\n<li>Del Carpio Hureta, Luis Paul<\/li>\n<li>Carne Martin, Sebastian Ciro<\/li>\n<li>Mar\u00edn Jim\u00e9nez, Juan Antonio<\/li>\n<li>Fiol Mata, Pau<\/li>\n<li>Perez Vazquez, Carla<\/li>\n<\/ul>\n\t\t\t\t\t\tScientific support\n\t\t\t\t\t\t\t\t\t\t\t<ul>\n<li>Torres Manjon, Silvia<\/li>\n<li>Codony Servat, Carles<\/li>\n<li>Mu\u00f1oz Merino, Ainhoa<\/li>\n<\/ul>\n<h2>\n\t\tRelated news\n\t<\/h2>\n\t<meta itemscope itemprop=\"mainEntityOfPage\" itemtype=\"https:\/\/schema.org\/WebPage\" itemid=\"http:\/\/23469\" content=\"Scientists present an oncolytic virus targeting NK cells with great antitumor potential\" \/><meta itemprop=\"datePublished\" content=\"2024-01-12\" \/><meta itemprop=\"dateModified\" content=\"2024-01-12\" \/><meta itemprop=\"name\" content=\"IDIBELL\"\/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/en\/wp-content\/uploads\/sites\/2\/2022\/05\/Marca-B-e1651478109730.png\"\/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/en\/author\/comunicacio\/\" \/><meta itemprop=\"name\" content=\"comunicacio\" \/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/en\/wp-content\/uploads\/sites\/2\/2024\/01\/NO001-Adenovirus-oncolitic-169-g.jpg\" \/><meta itemprop=\"width\" content=\"1366\" \/><meta itemprop=\"height\" content=\"769\" \/><meta itemprop=\"interactionType\" content=\"https:\/\/schema.org\/CommentAction\" \/><meta itemprop=\"userInteractionCount\" content=\"0\" \/>\t\n\t\t\t\t<a href=\"https:\/\/idibell.cat\/en\/2024\/01\/scientists-present-an-oncolytic-virus-targeting-nk-cells-with-great-antitumor-potential\/\" title=\"Scientists present an oncolytic virus targeting NK cells with great antitumor potential\"><\/a>\n\t\t\t<a href=\"https:\/\/idibell.cat\/en\/2024\/01\/scientists-present-an-oncolytic-virus-targeting-nk-cells-with-great-antitumor-potential\/\" title=\"Scientists present an oncolytic virus targeting NK cells with great antitumor potential\">Scientists present an oncolytic virus targeting NK cells with great antitumor potential<\/a>\n\t\t\tBy <a href=\"https:\/\/idibell.cat\/en\/author\/comunicacio\/\">comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t  |  \n\t\t\t\t\t\t\t\t\t12\/01\/2024\t\t\t\t\t\t\t\n\t<meta itemscope itemprop=\"mainEntityOfPage\" itemtype=\"https:\/\/schema.org\/WebPage\" itemid=\"http:\/\/21972\" content=\"A drug that prevents DNA reparation could improve the survival of patients with one of the most aggressive prostate cancers\" \/><meta itemprop=\"datePublished\" content=\"2023-02-23\" \/><meta itemprop=\"dateModified\" content=\"2023-02-28\" \/><meta itemprop=\"name\" content=\"IDIBELL\"\/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/en\/wp-content\/uploads\/sites\/2\/2022\/05\/Marca-B-e1651478109730.png\"\/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/en\/author\/comunicacio\/\" \/><meta itemprop=\"name\" content=\"comunicacio\" \/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/en\/wp-content\/uploads\/sites\/2\/2023\/02\/NP05-JM-Piulats_NEJM-Imatge-noti.jpg\" \/><meta itemprop=\"width\" content=\"1366\" \/><meta itemprop=\"height\" content=\"768\" \/><meta itemprop=\"interactionType\" content=\"https:\/\/schema.org\/CommentAction\" \/><meta itemprop=\"userInteractionCount\" content=\"0\" \/>\t\n\t\t\t\t<a href=\"https:\/\/idibell.cat\/en\/2023\/02\/a-drug-that-prevents-dna-reparation-could-improve-the-survival-of-patients-with-one-of-the-most-aggressive-prostate-cancers\/\" title=\"A drug that prevents DNA reparation could improve the survival of patients with one of the most aggressive prostate cancers\"><\/a>\n\t\t\t<a href=\"https:\/\/idibell.cat\/en\/2023\/02\/a-drug-that-prevents-dna-reparation-could-improve-the-survival-of-patients-with-one-of-the-most-aggressive-prostate-cancers\/\" title=\"A drug that prevents DNA reparation could improve the survival of patients with one of the most aggressive prostate cancers\">A drug that prevents DNA reparation could improve the survival of patients with one of the most aggressive prostate cancers<\/a>\n\t\t\tBy <a href=\"https:\/\/idibell.cat\/en\/author\/comunicacio\/\">comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t  |  \n\t\t\t\t\t\t\t\t\t23\/02\/2023\t\t\t\t\t\t\t\n\t<meta itemscope itemprop=\"mainEntityOfPage\" itemtype=\"https:\/\/schema.org\/WebPage\" itemid=\"http:\/\/19339\" content=\"We close a 2021 full of science!\" \/><meta itemprop=\"datePublished\" content=\"2021-12-30\" \/><meta itemprop=\"dateModified\" content=\"2021-12-23\" \/><meta itemprop=\"name\" content=\"IDIBELL\"\/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/en\/wp-content\/uploads\/sites\/2\/2022\/05\/Marca-B-e1651478109730.png\"\/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/en\/author\/comunicacio\/\" \/><meta itemprop=\"name\" content=\"comunicacio\" \/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/en\/wp-content\/uploads\/sites\/2\/2021\/12\/NO123-Best-2021-Imatge.jpg\" \/><meta itemprop=\"width\" content=\"1366\" \/><meta itemprop=\"height\" content=\"768\" \/><meta itemprop=\"interactionType\" content=\"https:\/\/schema.org\/CommentAction\" \/><meta itemprop=\"userInteractionCount\" content=\"0\" \/>\t\n\t\t\t\t<a href=\"https:\/\/idibell.cat\/en\/2021\/12\/we-close-a-2021-full-of-science\/\" title=\"We close a 2021 full of science!\"><\/a>\n\t\t\t<a href=\"https:\/\/idibell.cat\/en\/2021\/12\/we-close-a-2021-full-of-science\/\" title=\"We close a 2021 full of science!\">We close a 2021 full of science!<\/a>\n\t\t\tBy <a href=\"https:\/\/idibell.cat\/en\/author\/comunicacio\/\">comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t  |  \n\t\t\t\t\t\t\t\t\t30\/12\/2021\t\t\t\t\t\t\t\n\t<meta itemscope itemprop=\"mainEntityOfPage\" itemtype=\"https:\/\/schema.org\/WebPage\" itemid=\"http:\/\/18921\" content=\"IDIBELL receives more than one and a half million euros from AECC to fund cancer research projects\" \/><meta itemprop=\"datePublished\" content=\"2021-11-17\" \/><meta itemprop=\"dateModified\" content=\"2022-12-20\" \/><meta itemprop=\"name\" content=\"IDIBELL\"\/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/en\/wp-content\/uploads\/sites\/2\/2022\/05\/Marca-B-e1651478109730.png\"\/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/en\/author\/comunicacio\/\" \/><meta itemprop=\"name\" content=\"comunicacio\" \/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/en\/wp-content\/uploads\/sites\/2\/2021\/11\/logo.jpg\" \/><meta itemprop=\"width\" content=\"1366\" \/><meta itemprop=\"height\" content=\"768\" \/><meta itemprop=\"interactionType\" content=\"https:\/\/schema.org\/CommentAction\" \/><meta itemprop=\"userInteractionCount\" content=\"0\" \/>\t\n\t\t\t\t<a href=\"https:\/\/idibell.cat\/en\/2021\/11\/idibell-receives-more-than-one-and-a-half-million-euros-from-aecc-to-fund-cancer-research-projects\/\" title=\"IDIBELL receives more than one and a half million euros from AECC to fund cancer research projects\"><\/a>\n\t\t\t<a href=\"https:\/\/idibell.cat\/en\/2021\/11\/idibell-receives-more-than-one-and-a-half-million-euros-from-aecc-to-fund-cancer-research-projects\/\" title=\"IDIBELL receives more than one and a half million euros from AECC to fund cancer research projects\">IDIBELL receives more than one and a half million euros from AECC to fund cancer research projects<\/a>\n\t\t\tBy <a href=\"https:\/\/idibell.cat\/en\/author\/comunicacio\/\">comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t  |  \n\t\t\t\t\t\t\t\t\t17\/11\/2021\t\t\t\t\t\t\t\n\t<meta itemscope itemprop=\"mainEntityOfPage\" itemtype=\"https:\/\/schema.org\/WebPage\" itemid=\"http:\/\/18490\" content=\"A new drug increases the life expectancy of patients with very aggressive intraocular cancer\" \/><meta itemprop=\"datePublished\" content=\"2021-09-27\" \/><meta itemprop=\"dateModified\" content=\"2021-09-27\" \/><meta itemprop=\"name\" content=\"IDIBELL\"\/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/en\/wp-content\/uploads\/sites\/2\/2022\/05\/Marca-B-e1651478109730.png\"\/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/en\/author\/comunicacio\/\" \/><meta itemprop=\"name\" content=\"comunicacio\" \/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/en\/wp-content\/uploads\/sites\/2\/2021\/09\/NP23-NEJM-Piulats-melanoma-Imatge.jpg\" \/><meta itemprop=\"width\" content=\"1366\" \/><meta itemprop=\"height\" content=\"768\" \/><meta itemprop=\"interactionType\" content=\"https:\/\/schema.org\/CommentAction\" \/><meta itemprop=\"userInteractionCount\" content=\"0\" \/>\t\n\t\t\t\t<a href=\"https:\/\/idibell.cat\/en\/2021\/09\/a-new-drug-increases-the-life-expectancy-of-patients-with-very-aggressive-intraocular-cancer\/\" title=\"A new drug increases the life expectancy of patients with very aggressive intraocular cancer\"><\/a>\n\t\t\t<a href=\"https:\/\/idibell.cat\/en\/2021\/09\/a-new-drug-increases-the-life-expectancy-of-patients-with-very-aggressive-intraocular-cancer\/\" title=\"A new drug increases the life expectancy of patients with very aggressive intraocular cancer\">A new drug increases the life expectancy of patients with very aggressive intraocular cancer<\/a>\n\t\t\tBy <a href=\"https:\/\/idibell.cat\/en\/author\/comunicacio\/\">comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t  |  \n\t\t\t\t\t\t\t\t\t27\/09\/2021\t\t\t\t\t\t\t\n\t<meta itemscope itemprop=\"mainEntityOfPage\" itemtype=\"https:\/\/schema.org\/WebPage\" itemid=\"http:\/\/5088\" content=\"Molecular analysis could improve the early detection and prevention of endometrial cancer\" \/><meta itemprop=\"datePublished\" content=\"2019-06-17\" \/><meta itemprop=\"dateModified\" content=\"2021-07-28\" \/><meta itemprop=\"name\" content=\"IDIBELL\"\/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/en\/wp-content\/uploads\/sites\/2\/2022\/05\/Marca-B-e1651478109730.png\"\/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/en\/author\/erigin\/\" \/><meta itemprop=\"name\" content=\"Idibell\" \/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/en\/wp-content\/uploads\/sites\/2\/2020\/05\/foto_screenwide-1-scaled.jpg\" \/><meta itemprop=\"width\" content=\"2560\" \/><meta itemprop=\"height\" content=\"1920\" \/><meta itemprop=\"interactionType\" content=\"https:\/\/schema.org\/CommentAction\" \/><meta itemprop=\"userInteractionCount\" content=\"0\" \/>\t\n\t\t\t\t<a href=\"https:\/\/idibell.cat\/en\/2019\/06\/molecular-analysis-could-improve-the-early-detection-and-prevention-of-endometrial-cancer\/\" title=\"Molecular analysis could improve the early detection and prevention of endometrial cancer\"><\/a>\n\t\t\t<a href=\"https:\/\/idibell.cat\/en\/2019\/06\/molecular-analysis-could-improve-the-early-detection-and-prevention-of-endometrial-cancer\/\" title=\"Molecular analysis could improve the early detection and prevention of endometrial cancer\">Molecular analysis could improve the early detection and prevention of endometrial cancer<\/a>\n\t\t\tBy <a href=\"https:\/\/idibell.cat\/en\/author\/erigin\/\">Idibell<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t  |  \n\t\t\t\t\t\t\t\t\t17\/06\/2019\t\t\t\t\t\t\t\n\t<meta itemscope itemprop=\"mainEntityOfPage\" itemtype=\"https:\/\/schema.org\/WebPage\" itemid=\"http:\/\/5377\" content=\"El Grupo CataLands Solidaris da 10.000 euros al Programa ProCURE\" \/><meta itemprop=\"datePublished\" content=\"2017-07-31\" \/><meta itemprop=\"dateModified\" content=\"2021-07-28\" \/><meta itemprop=\"name\" content=\"IDIBELL\"\/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/en\/wp-content\/uploads\/sites\/2\/2022\/05\/Marca-B-e1651478109730.png\"\/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/en\/author\/erigin\/\" \/><meta itemprop=\"name\" content=\"Idibell\" \/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/en\/wp-content\/uploads\/sites\/2\/2020\/05\/20170731_IDIBELL_CataLands-1-scaled.jpg\" \/><meta itemprop=\"width\" content=\"2560\" \/><meta itemprop=\"height\" content=\"1920\" \/><meta itemprop=\"interactionType\" content=\"https:\/\/schema.org\/CommentAction\" \/><meta itemprop=\"userInteractionCount\" content=\"0\" \/>\t\n\t\t\t\t<a href=\"https:\/\/idibell.cat\/en\/2017\/07\/el-grupo-catalands-solidaris-da-10-000-euros-al-programa-procure\/\" title=\"El Grupo CataLands Solidaris da 10.000 euros al Programa ProCURE\"><\/a>\n\t\t\t<a href=\"https:\/\/idibell.cat\/en\/2017\/07\/el-grupo-catalands-solidaris-da-10-000-euros-al-programa-procure\/\" title=\"El Grupo CataLands Solidaris da 10.000 euros al Programa ProCURE\">El Grupo CataLands Solidaris da 10.000 euros al Programa ProCURE<\/a>\n\t\t\tBy <a href=\"https:\/\/idibell.cat\/en\/author\/erigin\/\">Idibell<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t  |  \n\t\t\t\t\t\t\t\t\t31\/07\/2017\t\t\t\t\t\t\t\n\t<meta itemscope itemprop=\"mainEntityOfPage\" itemtype=\"https:\/\/schema.org\/WebPage\" itemid=\"http:\/\/5501\" content=\"IDIBELL joins the ADVANCECAT project to promote advanced therapies in Catalonia\" \/><meta itemprop=\"datePublished\" content=\"2016-11-11\" \/><meta itemprop=\"dateModified\" content=\"2022-12-13\" \/><meta itemprop=\"name\" content=\"IDIBELL\"\/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/en\/wp-content\/uploads\/sites\/2\/2022\/05\/Marca-B-e1651478109730.png\"\/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/en\/author\/erigin\/\" \/><meta itemprop=\"name\" content=\"Idibell\" \/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/en\/wp-content\/uploads\/sites\/2\/2020\/05\/20161111_ADVANCECAT-1.jpg\" \/><meta itemprop=\"width\" content=\"568\" \/><meta itemprop=\"height\" content=\"320\" \/><meta itemprop=\"interactionType\" content=\"https:\/\/schema.org\/CommentAction\" \/><meta itemprop=\"userInteractionCount\" content=\"0\" \/>\t\n\t\t\t\t<a href=\"https:\/\/idibell.cat\/en\/2016\/11\/idibell-joins-the-advancecat-project-to-promote-advanced-therapies-in-catalonia\/\" title=\"IDIBELL joins the ADVANCECAT project to promote advanced therapies in Catalonia\"><\/a>\n\t\t\t<a href=\"https:\/\/idibell.cat\/en\/2016\/11\/idibell-joins-the-advancecat-project-to-promote-advanced-therapies-in-catalonia\/\" title=\"IDIBELL joins the ADVANCECAT project to promote advanced therapies in Catalonia\">IDIBELL joins the ADVANCECAT project to promote advanced therapies in Catalonia<\/a>\n\t\t\tBy <a href=\"https:\/\/idibell.cat\/en\/author\/erigin\/\">Idibell<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t  |  \n\t\t\t\t\t\t\t\t\t11\/11\/2016\t\t\t\t\t\t\t\n\t<meta itemscope itemprop=\"mainEntityOfPage\" itemtype=\"https:\/\/schema.org\/WebPage\" itemid=\"http:\/\/6466\" content=\"AECC grants two IDIBELL research projects\" \/><meta itemprop=\"datePublished\" content=\"2013-01-30\" \/><meta itemprop=\"dateModified\" content=\"2022-02-23\" \/><meta itemprop=\"name\" content=\"IDIBELL\"\/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/en\/wp-content\/uploads\/sites\/2\/2022\/05\/Marca-B-e1651478109730.png\"\/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/en\/author\/erigin\/\" \/><meta itemprop=\"name\" content=\"Idibell\" \/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/en\/wp-content\/uploads\/sites\/2\/2013\/01\/Captura-de-pantalla-2019-01-22-a-las-21.07.12.jpg\" \/><meta itemprop=\"width\" content=\"1366\" \/><meta itemprop=\"height\" content=\"768\" \/><meta itemprop=\"interactionType\" content=\"https:\/\/schema.org\/CommentAction\" \/><meta itemprop=\"userInteractionCount\" content=\"0\" \/>\t\n\t\t\t\t<a href=\"https:\/\/idibell.cat\/en\/2013\/01\/aecc-grants-two-idibell-research-projects\/\" title=\"AECC grants two IDIBELL research projects\"><\/a>\n\t\t\t<a href=\"https:\/\/idibell.cat\/en\/2013\/01\/aecc-grants-two-idibell-research-projects\/\" title=\"AECC grants two IDIBELL research projects\">AECC grants two IDIBELL research projects<\/a>\n\t\t\tBy <a href=\"https:\/\/idibell.cat\/en\/author\/erigin\/\">Idibell<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t  |  \n\t\t\t\t\t\t\t\t\t30\/01\/2013\t\t\t\t\t\t\t\n\t<meta itemscope itemprop=\"mainEntityOfPage\" itemtype=\"https:\/\/schema.org\/WebPage\" itemid=\"http:\/\/6908\" content=\"Manuel Ramirez: &#8221;Once we have made the step from the laboratory to the patient, we must return to the laboratory for further progress&#8221;\" \/><meta itemprop=\"datePublished\" content=\"2011-06-14\" \/><meta itemprop=\"dateModified\" content=\"2020-05-15\" \/><meta itemprop=\"name\" content=\"IDIBELL\"\/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/en\/wp-content\/uploads\/sites\/2\/2022\/05\/Marca-B-e1651478109730.png\"\/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/en\/author\/erigin\/\" \/><meta itemprop=\"name\" content=\"Idibell\" \/><meta itemprop=\"interactionType\" content=\"https:\/\/schema.org\/CommentAction\" \/><meta itemprop=\"userInteractionCount\" content=\"0\" \/>\t\n\t\t\t\t<a href=\"https:\/\/idibell.cat\/en\/2011\/06\/manuel-ramirez-once-we-have-made-the-step-from-the-laboratory-to-the-patient-we-must-return-to-the-laboratory-for-further-progress\/\" title=\"Manuel Ramirez: &#8221;Once we have made the step from the laboratory to the patient, we must return to the laboratory for further progress&#8221;\"><\/a>\n\t\t\t<a href=\"https:\/\/idibell.cat\/en\/2011\/06\/manuel-ramirez-once-we-have-made-the-step-from-the-laboratory-to-the-patient-we-must-return-to-the-laboratory-for-further-progress\/\" title=\"Manuel Ramirez: &#8221;Once we have made the step from the laboratory to the patient, we must return to the laboratory for further progress&#8221;\">Manuel Ramirez: &#8221;Once we have made the step from the laboratory to the patient, we must return to the laboratory for further progress&#8221;<\/a>\n\t\t\tBy <a href=\"https:\/\/idibell.cat\/en\/author\/erigin\/\">Idibell<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t  |  \n\t\t\t\t\t\t\t\t\t14\/06\/2011\t\t\t\t\t\t\t\n\t\t<!-- .pp-content-posts -->\n\n","protected":false},"excerpt":{"rendered":"<p>Cancer immunotherapy Summary The Cancer Virotherapy and Immunotherapy Group explores new anticancer treatments based on oncolytic adenoviruses and other immunotherapies. The group aims to design and evaluate oncolytic adenoviruses as antitumour agents for various solid tumours. The main lines of research are tumour targets, intratumoural diffusion through stromal barriers and oncolytic immunotherapy. The group also [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":448,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"site-sidebar-layout":"no-sidebar","site-content-layout":"page-builder","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"disabled","ast-breadcrumbs-content":"","ast-featured-img":"disabled","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"class_list":["post-2391","page","type-page","status-publish","hentry"],"publishpress_future_action":{"enabled":false,"date":"2025-01-25 04:07:47","action":"change-status","newStatus":"draft","terms":[],"taxonomy":""},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/pages\/2391","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/comments?post=2391"}],"version-history":[{"count":11,"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/pages\/2391\/revisions"}],"predecessor-version":[{"id":25001,"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/pages\/2391\/revisions\/25001"}],"up":[{"embeddable":true,"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/pages\/448"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/media?parent=2391"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}